Currently, children under 5 are the only age group without access to a COVID-19 vaccine in the United States.
In a statement, the American Academy of Pediatrics said they were encouraged by the news, but that they would like the data to be released.
Pediatricians have seen firsthand the fear, stress and hardship that so many families of young children have endured as they await a vaccine,” the AAP said in a statement. “We urge a transparent and data-driven process to evaluate this vaccine for this age group and look forward to offering its protection to our youngest children.”
In December, Pfizer and BioNTech announced they were changing the clinical trials for children under age 5 to add a third vaccine dose.
The reason for the change was that a two-dose regimen did not stimulate a protective immune response for young children against COVID-19, according to a press release.
There were no safety concerns identified, according to the press release.
